| | |
| Clinical data | |
|---|---|
| Other names | 3-Methoxy-4,5-ethylenedioxyamphetamine; 5-Methoxy-3,4-ethylenedioxyamphetamine; 5-Methoxy-EDA; 5-MeO-EDA |
| Routes of administration | Oral [1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C12H17NO3 |
| Molar mass | 223.272 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
MEDA, also known as 3-methoxy-4,5-ethylenedioxyamphetamine or as 5-methoxy-EDA, is a chemical compound of the phenethylamine, amphetamine, and EDxx families. [1] [2] It is the EDxx analogue of MMDA (5-methoxy-MDA). [1] [2] [3] The compound was first synthesized by Alexander Shulgin. [1] [2] In his book PiHKAL , the minimum dose is listed as 200 mg, and the duration as unknown. [1] [2] MEDA produced few to no effects. [1] [2] Very little data exists about the pharmacological properties, metabolism, and toxicity of MEDA. [1] [2] MEDA was first described in the scientific literature by Shulgin in 1964. [3] [1] [2]